Xencor moves on without Amgen, ditching its hopes in arthritis

Damian Garde

has reacquired the rights to an -optioned antibody, walking away from the Big Biotech and an indication with of a new path in rare disease.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS